search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


De invloed van anti-kanker medicijn geinduceerd hand-voet syndroom of hand-voet huid reactie op papillairlijnen van de vingers en kwaliteit van vingerafdrukkenidentificatie.


- candidate number15928
- NTR NumberNTR4332
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR23-dec-2013
- Secondary IDsMEC 2013-183 MEC ErasmusMC
- Public TitleDe invloed van anti-kanker medicijn geinduceerd hand-voet syndroom of hand-voet huid reactie op papillairlijnen van de vingers en kwaliteit van vingerafdrukkenidentificatie.
- Scientific TitleThe influence of anticancer drug-induced hand-foot syndrome and hand-foot skin reactions on friction ridges of the fingers and quality of fingerprints and fingerprint identification.
- ACRONYMFingerprints
- hypothesisUse of capecitabine, sorafenib and sunitinib may cause HFS or HFSR, which subsequently may lead to the disappearance of fingerprints.
- Healt Condition(s) or Problem(s) studied
- Inclusion criteria Patients using anti-cancer drugs (capecitabine, sunitinib, sorafenib) that are known for developing HFS or HFSR;
Age ≥ 18 years;
Written informed consent.
- Exclusion criteria Patients with symptomatic skin disease which affect hand palm and fingertips.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-aug-2013
- planned closingdate1-aug-2014
- Target number of participants100
- InterventionsOn three time points, at baseline, after 4- 6 weeks and at the end of treatment, fingerprints will be taken by one of the study coordinators by using a digital fingerprint scanner (present at outpatient clinic). A photograph of the hands will also be taken. If possible, fingerprints will also be taken 1 year after start of treatment.
- Primary outcome To examine whether systemic anti-cancer drug-induced HSF or HFSR leads to changes in or loss of friction ridges.
- Secondary outcome To compare the changes of friction ridges among patients.
To determine if the anti-cancer drug- induced HSF or HFSR leads to unidentifiable fingerprints for identification/individualization purposes using digital fingerprint scanners.
To determine whether the changes in friction ridges, caused by the anti- cancer drugs, are reversible when drug treatment is stopped.
- TimepointsOn three time points, at baseline, after 4- 6 weeks and at the end of treatment and if possible one year after treatment.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESMD PhD Ron H.J. Mathijssen
- CONTACT for SCIENTIFIC QUERIESMD PhD Ron H.J. Mathijssen
- Sponsor/Initiator Erasmus Medical Center, Department of Medical Oncology
- Funding
(Source(s) of Monetary or Material Support)
Erasmus Medical Center, Department of Medical Oncology
- Publicationsvan Doorn et al. Capecitabine and the Risk of Fingerprint Loss. JAMA Oncol. 2016 Aug 25 [Epub ahead of print]
- Brief summaryUse of capecitabine, sorafenib and sunitinib may cause HFS or HFSR, which subsequently may lead to the disappearance of fingerprints. In this exploratory prospective cohort study, we will examine whether anti-cancer drug-induced HFS or HFSR leads to changes of friction ridges and if these friction ridges changes eventually leads to unusable fingerprints for identification/individualization purposes using digital fingerprint scanners. This is of importance for society as a whole.
- Main changes (audit trail)
- RECORD23-dec-2013 - 12-okt-2016


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl